0
0
Home > Pharmaceuticals >  Dermatology >  Plaque Psoriasis – Epidemiology Forecast to 2030

Plaque Psoriasis – Epidemiology Forecast to 2030

Plaque psoriasis is a common and incurable chronic immune-mediated skin disease characterized by red and flaky patches that are itchy and can be painful during flareups which can last for several weeks to months (Mayo Clinic, 2020). Plaque psoriasis is the most common form of psoriasis, affecting between 80% and 90% of individuals living with psoriasis, and can occur on any area of the body such as the scalp, hands, and feet (National Psoriasis Foundation, 2018).

GlobalData epidemiologists relied on the most robust country-specific data for each segmentation covered in this forecast, obtained from scientific studies published in peer-reviewed academic journals, international healthcare agency publications, nationwide neonatal registries, and national disease surveillance agencies available at the time of publication. This report includes a 10-year forecast for the lifetime diagnosed prevalent cases of plaque psoriasis from 2020-2030. The prevalent cases of plaque psoriasis are further segmented by sex and age. Plaque psoriasis data are further segmented by severity (mild, moderate, and severe) and plaque psoriasis cases with psoriatic arthritis.

In the 7MM, the lifetime diagnosed prevalent cases of plaque psoriasis will increase from 15,726,350 in 2020 to 16,856,548 in 2030, at an Annual Growth Rate (AGR) of 0.72% per year. Similarly, lifetime diagnosed prevalent cases of psoriasis in the 5EU (France, Germany, Italy, Spain, and the UK) will increase at an AGR of 0.55%, from 7,779,141 in 2020 to 8,210,874 in 2030. When examining the AGR by individual markets, GlobalData estimates that the US will have the highest number of plaque psoriasis cases in 2030, with 8,171,859 cases at an AGR of 0.93%. Conversely, Japan will have the least number of cases by 2030, with 473,815 cases at an AGR of 0.08%.

Scope

The plaque psoriasis epidemiology report and model provide an overview of the risk factors, comorbidities, and global and historical trends for plaque psoriasis in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan).

The report includes a 10-year epidemiological forecast for the lifetime diagnosed prevalent cases of plaque psoriasis segmented by sex and age (0-17 years, 18-29 years, and by 10-year age groups for age 30 years up to 80 years and older) in these markets. The lifetime diagnosed prevalent cases are further segmented by severity and plaque psoriasis cases with psoriatic arthritis in the adult population. The epidemiology model corresponding to this report provides additional clinically relevant segmentations for the lifetime diagnosed prevalent cases of plaque psoriasis with scalp psoriasis and inflammatory bowel disease as well as severity and psoriatic arthritis in the pediatric population with plaque psoriasis.

The plaque psoriasis epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in plaque psoriasis.

The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The Plaque Psoriasis Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global plaque psoriasis markets.

Quantify patient populations in the global plaque psoriasis markets to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for plaque psoriasis therapeutics in each of the markets covered.

Understand magnitude of the plaque psoriasis population by age, sex, severity, and comorbidities.

Table of Contents

Table of Contents

| About GlobalData

1 Plaque Psoriasis: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.1.1 Risk Factors and Comorbidities

2.2 Global and Historical Trends

2.3 Forecast Methodology

2.3.1 Sources

2.3.2 Forecast Assumptions and Methods

2.4 Epidemiological Forecast for Plaque Psoriasis (2020-2030)

2.4.1 Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis

2.4.2 Age-Specific Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis

2.4.3 Sex-Specific Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis

2.4.4 Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis by Severity in the Adult Population

2.4.5 Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis with PsA in the Adult Population

2.5 Discussion

2.5.1 Epidemiological Forecast Insight

2.5.2 COVID-19 Impact

2.5.3 Limitations of the Analysis

2.5.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

3.3 Contact Us

List of Tables

Table 1: Summary of Newly Added Data Types and Countries

Table 2: Summary of Updated Data Types

Table 3: Risk Factors and Comorbidities for Plaque Psoriasis

List of Figures

Figure 1: 7MM, Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis, Both Sexes, All Ages, 2020 and 2030 (N)

Figure 2: 7MM, Lifetime Diagnosed Prevalence of Pediatric Plaque Psoriasis (%), Boys and Girls, Ages ≤17 Years, 2020

Figure 3: 7MM, Lifetime Diagnosed Prevalence of Adult Plaque Psoriasis (%), Men and Women, Ages ≥18 Years, 2020

Figure 4: Sources Used for Lifetime Diagnosed Prevalent Cases of Pediatric Plaque Psoriasis

Figure 5: Sources Used and Not Used for Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis in Adults

Figure 6: Sources Used for Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis by Severity Among Adults

Figure 7: Sources Used for Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis with PsA Among Adults

Figure 8: 7MM, Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis, Men and Women, All Ages, 2020 (N)

Figure 9: Age-Specific Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis, 7MM, Men and Women, 2020 (N)

Figure 10: 7MM, Sex-Specific Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis, All Ages, 2020 (N)

Figure 11: 7MM, Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis by Severity, Men and Women, ≥18 Years, 2020

Figure 12: 7MM, Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis with Psoriatic Arthritis, Men and Women, ≥18 Years, 2020 (N)

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports